Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy.

What Was Tested

The paper reports a study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), published as a randomized controlled trial.

HIV-associated adipose redistribution syndrome (HARS) is an HIV-associated disorder characterized by excess truncal fat, including visceral adipose tissue (VAT).

Who Took Part

The study group was 12, patients.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and multicenter.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Blinding on both sides kept the patients and researchers unaware of who received Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.

More than one site took part, so the patients came from several places.

Change in VAT was the primary outcome.

Key secondary outcomes included changes in non-high-density lipoprotein cholesterol (non-HDL-C) and limb fat.

What Was Measured

PubMed files the paper under topics including Anti-HIV Agents, Body Composition, Cholesterol, HIV-1, HIV-Associated Lipodystrophy Syndrome, Human Growth Hormone and Intra-Abdominal Fat.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 12, patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2007 (Journal of acquired immune deficiency syndromes (1999)), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.